Abl Bio Stock Fundamentals
| 298380 Stock | KRW 26,600 1,250 4.49% |
ABL Bio fundamentals help investors to digest information that contributes to ABL Bio's financial success or failures. It also enables traders to predict the movement of ABL Stock. The fundamental analysis module provides a way to measure ABL Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ABL Bio stock.
ABL |
ABL Bio Company Shares Outstanding Analysis
ABL Bio's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current ABL Bio Shares Outstanding | 45.3 M |
Most of ABL Bio's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ABL Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, ABL Bio has 45.3 M of shares currently outstending. This is 74.91% lower than that of the Healthcare sector and 57.6% lower than that of the Biotechnology industry. The shares outstanding for all Republic of Korea stocks is 92.08% higher than that of the company.
ABL Bio Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ABL Bio's current stock value. Our valuation model uses many indicators to compare ABL Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ABL Bio competition to find correlations between indicators driving ABL Bio's intrinsic value. More Info.ABL Bio is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value ABL Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ABL Bio's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
ABL Fundamentals
| Return On Equity | 5.6 | |||
| Return On Asset | -0.31 | |||
| Operating Margin | (6.16) % | |||
| Current Valuation | 866.33 B | |||
| Shares Outstanding | 45.3 M | |||
| Shares Owned By Insiders | 31.53 % | |||
| Shares Owned By Institutions | 12.89 % | |||
| Price To Sales | 101.38 X | |||
| Revenue | 5.33 B | |||
| Gross Profit | 8.06 B | |||
| EBITDA | (53.58 B) | |||
| Net Income | (43.56 B) | |||
| Cash And Equivalents | 21.59 B | |||
| Total Debt | 72.32 M | |||
| Debt To Equity | 1.40 % | |||
| Current Ratio | 14.71 X | |||
| Cash Flow From Operations | (40.61 B) | |||
| Beta | 1.08 | |||
| Market Capitalization | 958.17 B | |||
| Total Asset | 65.45 B | |||
| Net Asset | 65.45 B |
About ABL Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ABL Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ABL Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ABL Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio is traded on Korean Securities Dealers Automated Quotations in South Korea.
Pair Trading with ABL Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ABL Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ABL Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with ABL Stock
Moving against ABL Stock
The ability to find closely correlated positions to ABL Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ABL Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ABL Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ABL Bio to buy it.
The correlation of ABL Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ABL Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ABL Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ABL Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in ABL Stock
ABL Bio financial ratios help investors to determine whether ABL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ABL with respect to the benefits of owning ABL Bio security.